comprehensive -WSS

comprehensive

author：hotspot 2025-10-02 00:52:37 - browse：1864

Light hits on the portrait of George Washington on a one dollar bill. The portrait is surrounded by white and red tablets coming out of a pill bottle, as well as some coins — coverage from STAT — Adobe

WASHINGTON — Pharmaceutical companies are doing anything they can to stop President Biden’s Medicare program from being able to negotiate prices for their products, including suing the government. Experts say their efforts might actually benefit Biden by reminding voters that he’s taking on big drug companies.

When Democrats passed a law directing Medicare to negotiate drug prices, it was considered a major achievement. The new law, two decades in the making, gives Biden an accomplishment to both tout for himself and criticize Republicans for opposing — no Republicans voted to let Medicare negotiate drug prices.

Medicare price negotiation is popular with voters, as are the law’s price-inflation limits, and it includes additional, direct benefits for older adults that are easy to understand. It caps annual out-of-pocket retail-drug spending for seniors and people with disabilities, and it caps their monthly spending on insulin at $35.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： CMS should re

Wikipedia

entertainment

WSS

FDA needs staff influx to meet gene therapy needs, Marks says

After sickle

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Interest rates are at a 22

Trader Joe's recalls 10K cases of broccoli cheddar soup over potential foreign material

Pharma patents targeted by Biden in move to slash drug prices

focus

comprehensive

Wikipedia

Wildfire smoke exposes gaps in outdoor worker protections

Chemotherapy shortages won’t get better under Biden’s latest plan

State Dept. review finds Biden bears some blame for Afghanistan failures

FDA approves world's first CRISPR

Psychedelics group wrestles with new pharma identity

Radiology is caught between AI's potential and concern for patients

Medical records are filled with copy

Pregnancy discrimination could be enabled by AI

State Dept. review finds Biden bears some blame for Afghanistan failures

Congenital heart disease patients face new threat of heart failure

Wikipedia

Stoke drug shows lower activity against childhood epilepsy

Marc Tessier

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

AI models in health care face new federal disclosure requirements

Patients' immediate access to test results puts radiologists in a bind

Wikipedia

Wikipedia

entertainment

hotspot